Full-Time
Nationwide in-person and telehealth mental care
$20 - $21/hr
Remote in USA
Remote
See people who can refer or advise you
LifeStance Health provides mental health care across the United States through a network of about 4,000 clinicians, including psychiatrists, psychologists, and licensed therapists. With more than 450 centers in 31 states, it offers both in-person and telehealth appointments, making care flexible and accessible. The company focuses on personalized care plans tailored to each client’s needs and accepts most insurance plans to keep services affordable. Core services include diagnosis, therapy, and medication management delivered by a team of qualified professionals who work with individuals, families, and groups. Compared with others in the space, LifeStance leverages a large nationwide footprint, a mixed delivery model (in-person and telehealth), and a commitment to individualized treatment plans to reach a broad audience efficiently. Its goal is to improve access to trusted, affordable, and personalized mental healthcare so people can lead healthier, more fulfilling lives.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Bellevue, Washington
Founded
2017
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Parental Leave
Paid Vacation
Paid Holidays
1 stock quietly hitting new highs. By Mijuško Šibalić, Stock Market Writer and Stock Researcher September 2, 2026 10:57 PM PDT Dear WallStreetZen Member, This week, its Smart Leverage Alert centers on LifeStance Health (LFST). LifeStance Health is one of the largest outpatient mental-health providers in the country - a national network of therapists and psychiatrists delivering in-person and virtual care. After years of scaling, the business has just crossed an important line: it's now profitable, and the market is rewarding the turn. In its most recent quarter, reported August 6, LifeStance posted adjusted earnings of $0.06 per share, ahead of the $0.03 estimate, as revenue reached roughly $1.58 billion. More telling is the trajectory: both revenue and earnings are forecast to grow significantly faster than the broader Medical Care Facilities industry. This isn't a cheap stock, and WallStreetZen is not pretending it is. It trades at a premium because it's growing into a large, underserved market - and the price action agrees, with shares up more than 120% over the past year and pressing new highs. Wall Street is lined up behind it too: of the six analysts covering LFST, the consensus is a Strong Buy recommendation, with none rating it a sell. Its Zen Ratings model confirms the strength. LFST earns an A rating, which amounts to a Strong Buy recommendation, landing in the top 4% of more than 4,600 stocks. It's the #3-ranked stock in the A-rated Medical Care Facilities industry. Looking at the Component Grades that shape the overall grade, LFST ranks in the top 14% for Momentum, the top 2% for Sentiment, and the top 1% for Growth - a fast-growing business with real institutional conviction behind it. Its logic. With Zen Options Essentials, WallStreetZen use "Smart Leverage" - Deep-In-The-Money options that let you control shares for a fraction of the cost, with your maximum risk strictly defined from day one. The "Smart Leverage" Setup: LFST long call. Given the strong fundamental case and the momentum building behind LifeStance, here's how WallStreetZen is structuring the trade using Smart Leverage - Deep-In-The-Money calls that move nearly dollar-for-dollar with the stock, but with strictly defined risk from day one. Instead of committing about $5,040 to own 400 shares outright, four Deep-In-The-Money Calls let you control those same shares for about $1,352. * The Play: $10 Strike Call (Expiring Mar 19, 2027), 4 contracts * Delta: 0.8333 - Right in its sweet spot. This option moves nearly dollar-for-dollar with the stock. You get the upside with significantly less capital at risk. * Intrinsic Value: ~82% - More than four-fifths of what you pay is real value, not time decay. This is what separates a Smart Leverage setup from the kind of speculative options trades that blow up amateur accounts. * Leverage Multiple: 2.14x - Every dollar moves 2.1x harder than the stock, while the deep ITM strike still keeps meaningful downside protection versus a naked speculative call. * The Target: For this position to double (+100%), LFST only needs to reach approximately $16.76 - a roughly 29% move in the stock that produces a 100% return on the option premium. Why Options Over Shares? A 29% move in LFST stock would be a solid return for shareholders. In these Deep-In-The-Money options, that same move has the potential to double your investment while putting only about $1,352 at risk instead of $5,040. That's the power of Smart Leverage: stock-like upside with a fraction of the capital and strictly defined risk from day one. What to do next? LFST is just one of the setups its Zen Options Essentials TradeFinder identified this week. And the best part? You don't need to spend hours doing research to find these trades. The TradeFinder does the heavy lifting - scanning for Deep-In-The-Money options with the optimal Delta, the right Intrinsic Value, and the right Leverage Multiple - so you can evaluate a trade like this in minutes. How is that possible? Because the best options trades aren't about picking exotic strategies or timing the market perfectly. They're about finding great stocks...and using Smart Leverage to control your risk while amplifying your upside. EXACTLY what the Zen Ratings model is built to find. EXACTLY what this methodology has been delivering. If you'd like to see how this entire methodology works, start by watching its presentation, "Options Trading with the Zen Ratings." It walks through the Smart Leverage framework, the TradeFinder, and how WallStreetZen identify these opportunities step by step. Or, perhaps you are ready to start using Smart Leverage by becoming a Zen Options Essentials member. Click below to join: Happy Investing, Mijusko Sibalic Senior Writer, Zen Options Essentials (C) 2026 WallStreetZen Company. Stock tools. Stock ideas. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Virtus Advisers LLC acquired a new stake in LifeStance Health Group, Inc. (NASDAQ:LFST – Free Report) during the 2nd quarter, Holdings Channel reports. The institutional investor acquired 115,039 shares of the company’s stock, valued at approximately $1,232,000. A number of other large investors also recently bought and sold shares of the company. Assetmark Inc. lifted […]
LifeStance Health reported second quarter results that exceeded analyst expectations, with revenue of $435.4 million, a 5% beat on estimates. The mental healthcare provider's adjusted EBITDA of $66.04 million came in 21.9% above forecasts. CEO David Bourdon attributed the strong performance to clinician growth and operational efficiency. The company now employs over 8,500 clinicians and is operating at roughly 70% capacity, suggesting room for further productivity gains. The company raised its full-year revenue guidance to $1.71 billion from $1.66 billion and lifted EBITDA expectations to $225 million. Operating margin improved significantly to 7%, up from negative 0.9% in the prior year period. Management indicated that small acquisitions will help expand into new markets, whilst planned investments in technology and clinician compensation may temporarily pressure margins.
LifeStance Health reported strong second-quarter 2026 results, exceeding all guided metrics with revenue growth surpassing 26% and adjusted EBITDA margins above 15%. The mental healthcare provider's clinician base has grown to over 8,500 practitioners. Chief executive David Bourdon highlighted the company's operational execution and strong clinician productivity during the earnings call. The results prompted LifeStance to raise its full-year 2026 guidance across all metrics. Monica Prokocki, vice president of finance and investor relations, and chief financial officer Ryan McGroarty also participated in the call. The company's earnings release and presentation are available on its investor relations website. LifeStance attributed its performance to its value proposition resonating with clinicians and the strength of its operating model.
LifeStance Health Group reported Q1 revenues of $403.5 million, up 21.2% year on year and exceeding analyst expectations by 4.2%. The company, which provides outpatient mental health services through over 6,600 licensed professionals treating more than 880,000 patients annually across 33 states, posted net income growth of $13.5 million and adjusted EBITDA growth of 48%. The outpatient and specialty care sector showed strong overall performance in Q1, with the six tracked stocks beating consensus revenue estimates by 2%. Share prices in the sector have risen 62.4% on average since the latest earnings results. LifeStance's EBITDA and revenue guidance for the next quarter exceeded analyst expectations.